The information on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it and as such is considered to be a marketing communication.
- FX complexity - AUD/USD will be a benefit, however EUR/USD will headwind
- Healthcare multiples - are they justified?
- Product momentum and market position
Consensus expectations are for sales to increase 5.6% over the quarter to $407 million. Operational income is forecasted to be $111 million over the quarter with net profit at $88 million. Solid estimates, yet they would not be considered overly impressive.
Stock specific, current consensus is that mask sales in the US have been muted this quarter. However, the AirCurve generators look to have benefited from its launch mid-way through last year in both the US and European markets and should offset the mask sales issues, as this high-end product attracts a premium.
The sales growth may also be hampered by price cuts introduced in February which are still eating into margins and although no new cuts were introduced over the previous quarter, this cut is still having an impact.
Finally FX, AUD/USD will certainly give ResMed Inc a relief boost to earnings and should boost gross margins, however the EUR will be a major concern to total group revenues and that may negate the tail winds obtained from the AUD. Forecasts for the euro in 2015 are for it to be closer to parity, rather than $1.30 - the price the pair was at this time last year.